Current Therapeutic Research (Jan 2024)

Analysis of a Serious Adverse Reaction of Pulmonary Fibrosis Caused by Dronedarone

  • Yuyan Chen, PM,
  • Zhendong Fu, MM,
  • Xue Wen, MM,
  • Mingxia Zhang, PM,
  • Qiong Min, PM,
  • Peng Wang, PM,
  • Jin Zhang, MB,
  • Jun Ren, PM,
  • Wenbin Li, PD,
  • Rong Wang, PD

Journal volume & issue
Vol. 100
p. 100743

Abstract

Read online

Objective: This study aims to analyze a severe adverse reaction of pulmonary fibrosis induced by dronedarone hydrochloride tablets, and to provide a reference for clinical rational medication through drug precautions. Methods: A case of pulmonary fibrosis induced by dronedarone hydrochloride tablets, along with related literature was retrospectively analyzed. Results: Patients over 65 years old with a history of exposure to amiodarone may increase the incidence of pulmonary toxicity induced by dronedarone, and dronedarone should not be selected as a substitute treatment drug for patients with amiodarone-induced pulmonary toxicity. Conclusions: It is recommended that clinicians monitor the diffusion capacity of carbon monoxide and lung ventilation function of patients before and after using dronedarone for treatment. For patients with a history of amiodarone exposure, intermittent monitoring of chest X-rays and lung function is necessary. If lung function decreases, dronedarone should be immediately discontinued.

Keywords